Interview: Dr. Deborah Nash, Ibogaine and Miami Based DemeRX.

Dr Deborah Nash

Partnered with ATAI Life Sciences ATAI. Amazing Interview.

“I said there’s no way that you can take one dose of Ibogaine and have this complete reset, to use the word being used today. But it is indeed a reset and all withdrawals are blocked and people do get up and look like they’ve been transformed into a new person.” Deborah Nash M.D. 

DemeRx has reviewed patient data which demonstrate that a single dose of lbogaine is sufficient to detoxify opioid-dependent persons and diminish drug cravings for extended time periods.

DemeRx has evaluated the safety and pharmacokinetics of lbogaine and Noribogaine in normal healthy volunteers and in patients with opioid abuse problems.

We plan to advance lbogaine for opioid detoxification in medically supervised inpatient settings. Noribogaine will be developed as a low dose adjunct therapy for patients in early recovery among other indications.

RELATED: DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

RELATED: ATAI, DemeRx pursue ‘neurochemical reset’ for addiction in $22M JV

If you or a loved one struggle with addiction, this is an episode you’re going to want to listen to. Many of our current pharmaceuticals stem from compounds discovered in plant medicines. And many beneficial plants that were discovered decades ago still have huge potential for changing modern medicine—ibogaine is one of them. Today on The Doctor’s Farmacy, I’m excited to sit down with Dr. Deborah Mash to discuss the use of the African plant ibogaine and its metabolite, noribogaine, in the treatment of addiction and how it could impact the devastating opioid epidemic.

Dr. Deborah Mash is one of the world’s foremost experts on ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences—a global biotech platform with a special focus on psychedelic medicine—to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI are conducting a Clinical Phase I/II trial in opioid-dependent patients. This landmark trial will advance screening procedures, dosing guidelines, and best practices for opioid withdrawal management and relapse prevention.

Learn more about Dr. Mash’s work at

#Ibogaine, #Ibogine, #ATAI, $ATAI